Key result
Low eGFRcys is linked to ~2-fold higher cardiovascular risk in kidney transplant recipients.
Cohort (n=508)
Answers are grounded in this paper and cite their sources.
Cystatin C and beta-2-microglobulin (B2M) are filtration markers associated with adverse outcomes in nontransplant populations, sometimes with stronger associations than for creatinine. We evaluated associations of estimated glomerular filtration rate from cystatin C (eGFR cys ), B2M (eGFR B 2M ), and creatinine (eGFR cr ) with cardiovascular outcomes, mortality, and kidney failure in stable kidney transplant recipients using a case–cohort study nested within the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. A random subcohort was selected (N = 508; mean age 51.6 years, median transplant vintage 4 years, 38% women, 23.6% nonwhite race) with enrichment for cardiovascular events (N = 306; 54 within the subcohort), mortality (N = 208; 68 within the subcohort), and kidney failure (N = 208; 52 within the subcohort). Mean eGFR cr , eGFR cys , and eGFR B 2M were 46.0, 43.8, and 48.8 mL/min/1.73m 2 , respectively. After multivariable adjustment, hazard ratios for eGFR cys and eGFR B 2M <30 versus 60+ were 2.02 (95% confidence interval [CI] 1.09–3.76; p=0.03) and 2.56 (1.35–4.88; p=0.004) for cardiovascular events; 3.92 (2.11–7.31) and 4.09 (2.21–7.54; both p < 0.001) for mortality; and 9.49 (4.28–21.00) and 15.53 (6.99–34.51; both p < 0.001) for kidney failure. Associations persisted with additional adjustment for baseline eGFR cr . We conclude that cystatin C and B2M are strongly associated with cardiovascular events, mortality, and kidney failure in stable kidney transplant recipients.
No takes yet. Share an insight, caveat, or question.
Foster et al. (2017) conducted a cohort in Stable kidney transplant recipients (n=508). eGFR from cystatin C (eGFRcys) and beta-2-microglobulin (eGFRB2M) <30 mL/min/1.73m2 vs. eGFRcys and eGFRB2M ≥60 mL/min/1.73m2 was evaluated on Cardiovascular events, mortality, and kidney failure (reported here: cardiovascular events for eGFRcys <30 vs 60+) (HR 2.02, 95% CI 1.09-3.76, p=0.03). Low eGFRcys and eGFRB2M (<30 vs ≥60) predicted cardiovascular events, mortality, and kidney failure in kidney transplant recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: